埃万妥单抗联合兰泽替尼获批用于EGFR突变晚期NSCLC一线治疗，中位总生存期预计超4年

*仅供医学专业人士阅读参考

埃万妥单抗联合兰泽替尼方案正式获得NMPA批准，成为中国EGFR敏感突变晚期非小细胞肺癌一线治疗新增选择。

*以下内容仅供医疗卫生专业人士浏览。

参考文献：

[1]Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.

[2]Lu S, Byoung CC, Jong-Seok L, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.

[3]Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study. 2025 ELCC. 4O.

[4]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small cell LungCancer Version 7.2025.

[5]中国临床肿瘤学会（CSCO）非小细胞肺癌（NSCLC）诊疗指南（2025年）

[6]Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.

[7]Spira AI, Paz-Ares L, Han JY, et al. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr,a Phase 2 Study:A Brief Report.J Thorac Oncol. Published online January 24,2025.

[8]Nicolas G, Li WM, Alexander lS, et al.Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib:Early success of the COCOON trial.2025 ELCC. 10MO.

[9]Feldman JL, Cho BC, Li W, et al. Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial. 2025 ASCO. Abstract 8641.

审批编号：CP-551633 审批时间：11/11/2025 过期时间：11/11/2026

*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。